WO2004064760A3 - Aptamer therapeutics useful in ocular pharmacotherapy - Google Patents

Aptamer therapeutics useful in ocular pharmacotherapy Download PDF

Info

Publication number
WO2004064760A3
WO2004064760A3 PCT/US2004/001661 US2004001661W WO2004064760A3 WO 2004064760 A3 WO2004064760 A3 WO 2004064760A3 US 2004001661 W US2004001661 W US 2004001661W WO 2004064760 A3 WO2004064760 A3 WO 2004064760A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacotherapy
ocular
therapeutics useful
aptamer therapeutics
nucleic acid
Prior art date
Application number
PCT/US2004/001661
Other languages
French (fr)
Other versions
WO2004064760A2 (en
Inventor
David Epstein
Dilara Grate
Jeffrey Kurz
Nicholas Marsh
Thomas G Mccauley
Charles Wilson
Original Assignee
Archemix Corp
David Epstein
Dilara Grate
Jeffrey Kurz
Nicholas Marsh
Thomas G Mccauley
Charles Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp, David Epstein, Dilara Grate, Jeffrey Kurz, Nicholas Marsh, Thomas G Mccauley, Charles Wilson filed Critical Archemix Corp
Priority to EP04704120A priority Critical patent/EP1606301A4/en
Priority to CA002513004A priority patent/CA2513004A1/en
Priority to JP2006501092A priority patent/JP2006516288A/en
Priority to AU2004206955A priority patent/AU2004206955A1/en
Publication of WO2004064760A2 publication Critical patent/WO2004064760A2/en
Publication of WO2004064760A3 publication Critical patent/WO2004064760A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Abstract

The invention provides nucleic acid therapeutic compositions capable of binding to cytokines, growth factors and cell surface proteins, individually or in combinations of two or more, and methods for delivering these nucleic acid therapeutics in the treatment of glaucoma and other proliferative diseases of the eye.
PCT/US2004/001661 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy WO2004064760A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04704120A EP1606301A4 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy
CA002513004A CA2513004A1 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy
JP2006501092A JP2006516288A (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ophthalmic drug therapy
AU2004206955A AU2004206955A1 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US44134703P 2003-01-21 2003-01-21
US60/441,347 2003-01-21
US46309503P 2003-04-15 2003-04-15
US60/463,095 2003-04-15
US46417903P 2003-04-21 2003-04-21
US60/464,179 2003-04-21
US46505503P 2003-04-23 2003-04-23
US60/465,055 2003-04-23
US46962803P 2003-05-08 2003-05-08
US60/469,628 2003-05-08
US47468003P 2003-05-29 2003-05-29
US60/474,680 2003-05-29
US49101903P 2003-07-29 2003-07-29
US60/491,019 2003-07-29
US51207103P 2003-10-17 2003-10-17
US60/512,071 2003-10-17
US53704504P 2004-01-16 2004-01-16
US53720104P 2004-01-16 2004-01-16
US60/537,045 2004-01-16
US60/537,201 2004-01-16

Publications (2)

Publication Number Publication Date
WO2004064760A2 WO2004064760A2 (en) 2004-08-05
WO2004064760A3 true WO2004064760A3 (en) 2005-10-27

Family

ID=32777434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001661 WO2004064760A2 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy

Country Status (5)

Country Link
EP (1) EP1606301A4 (en)
JP (1) JP2006516288A (en)
AU (1) AU2004206955A1 (en)
CA (1) CA2513004A1 (en)
WO (1) WO2004064760A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8946184B2 (en) 2005-02-14 2015-02-03 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2007532662A (en) * 2004-04-13 2007-11-15 （オーエスアイ）アイテツク・インコーポレーテツド Nucleic acid aptamers conjugated to high molecular weight steric groups
EP2436391A3 (en) * 2004-11-02 2012-07-04 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006119643A1 (en) * 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
WO2007103549A2 (en) * 2006-03-08 2007-09-13 Archemix Corp. Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2010033248A2 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
JP2010100615A (en) * 2008-09-25 2010-05-06 Santen Pharmaceut Co Ltd Prophylactic or curative agent for retinal disease including polyalkylene glycol as active ingredient
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
JP6041373B2 (en) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 Aptamer molecule that binds to TNF-α
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
WO2013149086A1 (en) 2012-03-28 2013-10-03 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
CN110193009A (en) * 2013-07-12 2019-09-03 伊维希比奥公司 Method for treating or preventing ophthalmology disease
CA3221709A1 (en) 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
JP6883987B2 (en) * 2013-12-04 2021-06-09 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Methods for wound healing procedures utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
AU2016364431B2 (en) * 2015-12-04 2020-08-27 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018148333A1 (en) * 2017-02-08 2018-08-16 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2020120256A1 (en) * 2018-12-11 2020-06-18 Université De Strasbourg Aptamer and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS
US20020040015A1 (en) * 2000-02-10 2002-04-04 Miller Joan W. Methods and compositions for treating conditions of the eye
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS
US20020040015A1 (en) * 2000-02-10 2002-04-04 Miller Joan W. Methods and compositions for treating conditions of the eye

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIETRAS ET AL: "Inhibition of platelet-derived growth factor recetors reduces interstitial hypertentison and increases transcapillary transport in tumors", CANCER RESEARCH, vol. 61, April 2001 (2001-04-01), pages 2929 - 2934, XP002947975 *
See also references of EP1606301A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8946184B2 (en) 2005-02-14 2015-02-03 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders

Also Published As

Publication number Publication date
EP1606301A2 (en) 2005-12-21
EP1606301A4 (en) 2006-06-14
AU2004206955A1 (en) 2004-08-05
JP2006516288A (en) 2006-06-29
CA2513004A1 (en) 2004-08-05
WO2004064760A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004064760A3 (en) Aptamer therapeutics useful in ocular pharmacotherapy
WO2007044534A3 (en) Vegf analogs and methods of use
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006007560A3 (en) Targeted protein replacement for the treatment of lysosomal storage disorders
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
EP2239262A3 (en) Fused ring heterocycle kinase modulators
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
WO2005000215A3 (en) Methods for treating pain
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006104913A3 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
WO2007035922A3 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
WO2007011363A3 (en) Binding domain fusion proteins
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005123183A3 (en) Electroporation device and method for delivery to ocular tissue
ES2354824T3 (en) PIRAZOLO [1,5-A] USEFUL PYRIMIDINS AS INHIBITORS OF KINASE PROTEINS.
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
WO2005072223A3 (en) Engineered proteins, and methods of making and using
WO2005086835A3 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2008080045A3 (en) Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2009013461A8 (en) Growth hormone fusion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2513004

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006501092

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004206955

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004206955

Country of ref document: AU

Date of ref document: 20040121

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004704120

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004206955

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048048429

Country of ref document: CN

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004704120

Country of ref document: EP